SCHEMBL12666949

SCHEMBL12666949

CCCCCCC(=O)NNC(=O)c1ccco1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.63
▸ HDAC3 O15379 1/20 0.63
▸ GAA P10253 4/20 0.62
▸ MEN1 O00255 4/20 0.61
▸ KMT2A Q03164 4/20 0.61
▸ ALDH1A1 P00352 6/20 0.59
▸ KDM4E B2RXH2 2/20 0.57
▸ CYP2C9 P11712 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ MAPT P10636 1/20 0.55
▸ NLRP1 Q9C000 1/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ POLB P06746 1/20 0.53
▸ LMNA P02545 1/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254670 0.79 HDAC3 (0.91) HDAC3GAAMEN1KMT2AALDH1A1
SCHEMBL4373141 0.79 GAA (0.59) HPGDHDAC3GAAMEN1KMT2A
SCHEMBL18825687 0.79 GAA (0.59) HPGDHDAC3GAAMEN1KMT2A
SCHEMBL4369180 0.79 GAA (0.59) HPGDHDAC3GAAMEN1KMT2A
SCHEMBL18825664 0.79 GAA (0.59) HPGDHDAC3GAAMEN1KMT2A
SCHEMBL25222615 0.79 GAA (0.59) HPGDHDAC3GAAMEN1KMT2A
SCHEMBL4382929 0.79 GAA (0.59) HPGDHDAC3GAAMEN1KMT2A
SCHEMBL5634680 0.79 GAA (0.59) HPGDHDAC3GAAMEN1KMT2A
SCHEMBL10353082 0.79 GAA (0.59) HPGDHDAC3GAAMEN1KMT2A
SCHEMBL18825661 0.79 GAA (0.59) HPGDHDAC3GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105597-A1 Modulation of pathogenicity QUONOVA, LLC 2011-05-05 — — US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 — — US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 — — US disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 — — US disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 — — US disclosed
US-20080214635-A1 Modulation of pathogenicity QUONOVA, LLC 2008-09-04 — — US disclosed
US-20080214635-A1 Modulation of pathogenicity QUONOVA, LLC 2008-09-04 — — US disclosed
US-20080194588-A1 Modulation of pathogcnicity QUONOVA, LLC 2008-08-14 — — US disclosed
US-20080194607-A1 Modulation of pathogenicity QUONOVA, LLC 2008-08-14 — — US disclosed
US-20080194607-A1 Modulation of pathogenicity QUONOVA, LLC 2008-08-14 — — US disclosed
US-20080188536-A1 Modulation of pathogenicity QUONOVA, LLC 2008-08-07 — — US disclosed
US-20080188536-A1 Modulation of pathogenicity QUONOVA, LLC 2008-08-07 — — US disclosed
US-20080188491-A1 Modulation of pathogenicity QUONOVA, LLC 2008-08-07 — — US disclosed
US-20080188535-A1 Modulation of pathogenicity QUONOVA, LLC 2008-08-07 — — US disclosed
US-20080182878-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-31 — — US disclosed
US-20080182878-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-31 — — US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 — — US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 — — US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 — — US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194588-A1 Modulation of pathogcnicity NR4A1, NR4A2, NR3C2 HPGD 1157/4885HDAC3 1216/4885GAA 4075/4885
US-20090076012-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 HPGD 2540/4885HDAC3 1511/4885GAA 3227/4885
US-20110105597-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885
US-20080214635-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885
US-20100280036-A1 Modulation of Pathogenicity NR4A1, NR4A2, NR4A3 HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885
US-20080182878-A1 Modulation of pathogenicity NR4A1, NR4A2, MSR1 HPGD 2561/4885HDAC3 1498/4885GAA 3223/4885
US-20080188491-A1 Modulation of pathogenicity NR4A1, MSR1, NR4A2 HPGD 2727/4885HDAC3 1418/4885GAA 3503/4885
US-20080194607-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885
US-20080188535-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885
US-20080188536-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885
US-20080176938-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 HPGD 2629/4885HDAC3 1563/4885GAA 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback